Product category:
Proteomics
News Release from: AnaSpec | Subject: Mog (35-55)
Edited by the Laboratorytalk Editorial
Team on 20 September 2006
AnaSpec synthesises Mog peptides for MS
research
Myelin/oligodendrocyte glycoprotein (Mog) is a 26- to 28-kDa protein first described as a target antigen for the autoimmune demyelination response observed in animals immunized with CNS homogenates
Myelin/oligodendrocyte glycoprotein (Mog) is a member of the immunoglobulin superfamily expressed in the central nervous system (CNS) and located within the MHC Found on the surface of myelinating oligodendrocytes and external lamellae of myelin sheaths in the CNS, it is thought to be targeted by the autoimmune T cell response in multiple sclerosis (MS)
This article was originally published on Laboratorytalk on 18 Jun 2007 at 8.00am (UK)
Related stories
Industry's first and only anti-Mog Elisa kits
Drawing on its broad portfolio of Mog (35-55) and other multiple sclerosis (MS) experimental autoimmune encephalomyelitis (EAE)-related peptides, AnaSpec has released SensoLyte anti-Mog Elisa kits
Although this protein is a minor component of myelin proteins, MOG is a potent autoantigen which contributes extensively to the anti-myelin response and primary inflammatory demyelination in autoimmune diseases.
Several lines of evidence suggest that autoreactive antibodies are important in MS pathogenesis, however the pathophysiological significance of Mog-specific autoantibodies in MS/EAE is still controversial.
Subtle changes in Mog sequences dramatically influence disease susceptibility and T cell responses in vitro.
In its continuing effort to provide research solutions for MS, AnaSpec offers Mog (35-55), mouse, rat, a key peptide that induces severe chronic experimental autoimmune encephalomyelitis in transgenic mice.
• AnaSpec: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
